New chemo combo aims to cut side effects for elderly blood cancer patients
NCT ID NCT03352765
First seen Jan 04, 2026 · Last updated May 16, 2026 · Updated 24 times
Summary
This early-phase study tests a combination of three drugs (rituximab, bendamustine, and melphalan) followed by a stem cell transplant using the patient's own cells. The goal is to see if this gentler regimen causes fewer severe side effects than standard treatments for older adults with multiple myeloma or certain lymphomas. About 28 participants will be enrolled to find the safest dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.